Linerixibat

GSK's phase III GLISTEN trial demonstrates linerixibat significantly improves cholestatic pruritus (relentless itch) in patients with primary biliary cholangitis, addressing a major quality of life concern.

GSK's linerixibat met the primary endpoint in the Phase III GLISTEN study, demonstrating a statistically significant improvement in itch score for PBC patients.

GSK's linerixibat met its primary endpoint in the Phase 3 GLISTEN trial, demonstrating a statistically significant reduction in itch score for PBC patients with moderate-to-severe pruritus.

GSK's linerixibat demonstrated a statistically significant improvement in itch for primary biliary cholangitis (PBC) patients with cholestatic pruritus in the Phase III GLISTEN trial.

GSK's linerixibat met the primary endpoint in the GLISTEN phase III trial, demonstrating a statistically significant reduction in itch for PBC patients.